



ATTORNEYS AT LAW



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Horner  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim

Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Ellison  
Thomas C. Fiala  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Brian J. Del Buono  
Edward W. Yee  
Vincent L. Capuano  
Virgil Lee Beaston  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Rae Lynn P. Guest  
Daniel A. Klein

Jason D. Eisenberg  
Michael D. Specht  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longsworth  
Lori A. Gordon  
Laura A. Vogel  
Bryan S. Wade  
Bashir M.S. Ali  
Shannon A. Carroll  
Matthew E. Kelley  
Michelle K. Holoubek  
Marsha A. Rose\*

Christopher J. Walsh  
W. Blake Coblenz\*  
James J. Pohl\*  
Young Tang  
John T. Haran\*  
Mark W. Rygiel  
**Registered Patent Agents\***  
Karen R. Markowicz  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse

Liliana Di Nola-Baron  
Peter A. Socarras  
Jeffrey K. Mills  
Danielle L. Letting  
Lori Brandes

**Of Counsel**  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
#Practice Limited to  
Federal Agencies

July 11, 2006

**WRITER'S DIRECT NUMBER:**  
(202) 772-8846

**INTERNET ADDRESS:**  
PCALVO@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit: 1644**

**Attn: Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Application No. 10/551,209; § 371 Date: September 28, 2005  
For: **Methods of Identifying Optimal Variants of Peptide Epitopes**  
Inventors: **BAKER et al.**  
Our Ref: 2473.0260001/EKS/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Change of Attorney Docket Number Pleading;
2. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
3. Form PTO/SB/08A (2 pages) listing cited documents US1-US15 and FP1-FP21;
4. Form PTO/SB/08B (8 pages) listing cited documents NPL1-NPL77;
5. First Supplemental Disclosure Statement Under 37 C.F.R. § 1.97(b);
6. Form PTO/SB/08A (2 pages) listing cited documents US16-US35 and FP22-FP31;
7. Form PTO/SB/08B (8 pages) listing cited documents NPL80-NPL158;
8. Copies of cited documents FP1-FP31, NPL1-NPL76 and NPL80-NPL158; and
9. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are

Commissioner for Patents  
July 11, 2006  
Page 2

necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Mite M* Reg # 54,325

for Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913

EKS/PAC/CLD/amz  
Enclosures

555293\_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BAKER *et al.*

Application No.: 10/551,209

§ 371 Date: September 28, 2005

For: **Methods of Identifying Optimal Variants of Peptide Epitopes**

Confirmation No.: 8322

Art Unit: 1644

Examiner: *To be assigned*

Atty. Docket: 2473.0260001/EKS/PAC

**Request for Change of Attorney Docket Number Pleading**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the attorney docket number for the above-captioned application be changed from "2006.0260001/EKS/PAC" to -- 2473.0260001/EKS/PAC --. Kindly use this attorney docket number in any future correspondence addressed to the undersigned.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Wite W.* Reg #54,325  
for Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913

Date: July 11, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
524702v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 8322
BAKER <i>et al.</i>	Art Unit: 1644
Appl. No.: 10/551,209	Examiner: <i>To be assigned</i>
§ 371 Date: September 28, 2005	Atty. Docket: 2473.0260001/EKS/PAC
For: <b>Methods of Identifying Optimal Variants of Peptide Epitopes</b>	

**Information Disclosure Statement under 37 C.F.R. § 1.97(b)**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1-FP21** and **NPL1-NPL76** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US1** to **US15**, cited on the attached IDS Form, PTO/SB/08A, are not submitted. In addition, a copy of documents **NPL77** is not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent

application (or portion of the application which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **FP2**, **FP5**, and **FP8** cited on Form PTO/SB/08A:

Document **FP2**, EP 0 226 513 A1, is in a foreign language. An English language abstract of document FP2 is attached as Document **NPL74**.

Document **FP5**, WO 92/21033 A1, is in a foreign language. An English language abstract of document FP5 is attached as Document **NPL75**.

Document **FP8**, WO 94/11738 A1, is in a foreign language. An English language abstract of document FP8 is attached as Document **NPL76**.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 09/189,702, inventors Sette *et al.*, filed November 10, 1998; pending and listed on accompanying PTO/SB/08B as Document **NPL77**.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Wit M* Reg #54,325  
for Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913

Date: July 11, 2016  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
520291v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO

*Complete if Known***INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet	1	of	2	Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
				Attorney Docket Number	2473.0260001/EKS/PAC

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pages, Columns, Lines
		Number-Kind Code <sup>2</sup> (If Known)			
US1	5,200,320		04/06/1993	Sette <i>et al.</i>	
US2	5,503,829		04/02/1996	Ladant <i>et al.</i>	
US3	5,662,907		09/02/1997	Kubo <i>et al.</i>	
US4	5,846,827		12/08/1998	Celis <i>et al.</i>	
US5	6,034,214		03/07/2000	Boon <i>et al.</i>	
US6	6,413,517		07/02/2002	Sette <i>et al.</i>	
US7	2002/0098197 A1		07/25/2002	Sette <i>et al.</i>	
US8	2002/0160019 A1		10/31/2002	Sette <i>et al.</i>	
US9	2002/0177694 A1		11/28/2002	Sette <i>et al.</i>	
US10	6,534,482		03/18/2003	Fikes <i>et al.</i>	
US11	2003/0099634 A1		05/29/2003	Vitiello <i>et al.</i>	
US12	2003/0152580 A1		08/14/2003	Sette <i>et al.</i>	
US13	2003/0185822 A1		10/02/2003	Grey <i>et al.</i>	
US14	2003/0203869 A1		10/30/2003	Fikes <i>et al.</i>	
US15	2003/0220285 A1		11/27/2003	Fikes <i>et al.</i>	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pages, Columns, Lines	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup>				
FP1	EP 0 044 710 A1		01/27/1982	Scripps Clinic & Research Foundation		
FP2	EP 0 226 513 A1		06/24/1987	Institut Pasteur		Abs
FP3	WO 92/02543 A1		02/20/1992	Cytel Corp. <i>et al.</i>		
FP4	WO 92/12996 A2		08/06/1992	Immune Response Corp.		
FP5	WO 92/21033 A1		11/26/1992	Max-Planck-Gesellschaft		Abs
FP6	WO 93/03764 A1		03/04/1993	Cytel Corp.		
FP7	WO 94/03205 A1		02/17/1994	Cytel Corp.		
FP8	WO 94/11738 A1		05/26/1994	Max-Planck-Gesellschaft		Abs
FP9	WO 94/20127 A1		09/15/1994	Cytel Corp.		
FP10	WO 95/04817 A1		02/16/1995	Cytel Corp.		
FP11	WO 95/22317 A1		08/24/1995	Cytel Corp.		
FP12	WO 96/03140 A1		02/08/1996	Cytel Corp.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	<i>To Be Assigned</i>
Sheet	2	of	2	Attorney Docket Number	2473.0260001/EKS/PAC

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pages, Columns, Lines	T <sup>6</sup>
		Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>5</sup>				
	FP13	WO 97/33602 A1	09/18/1997	Cytel Corp.		
	FP14	WO 97/34621 A1	09/25/1997	Cytel Corp.		
	FP15	WO 98/32456 A1	07/30/1998	Epimmune Inc.		
	FP16	WO 99/45954 A1	09/16/1999	Epimmune Inc.		
	FP17	WO 99/58658 A2	11/18/1999	Epimmune Inc.		
	FP18	WO 99/61916 A1	12/02/1999	Epimmune Inc.		
	FP19	WO 99/65522 A1	12/23/1999	Epimmune Inc.		
	FP20	WO 02/20616	03/14/2002	Epimmune Inc.		
	FP21	WO 02/061435 A2	08/08/2002	Epimmune Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet 1 of 8		Attorney Docket Number 2473.0260001/EKS/PAC			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T <sup>2</sup>
	NPL1	Aichele, P., <i>et al.</i> , "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," <i>J. Exp. Med.</i> 171:1815-1820, Rockefeller University Press (1990)	
	NPL2	Alexander, J., <i>et al.</i> , "Derivation of HLA-A11/K <sup>b</sup> Transgenic Mice. Functional CTL Repertoire and Recognition of Human A11-Restricted CTL Epitopes," <i>J. Immunol.</i> 159:4753-4761, The American Association of Immunologists (1997)	
	NPL3	Bergmann, C.C., <i>et al.</i> , "Differential Effects of Flanking Residues on Presentation of Epitopes from Chimeric Peptides," <i>J. Virol.</i> 68:5306-5310, American Society for Microbiology (1994)	
	NPL4	Bertoni, R., <i>et al.</i> , "Human Histocompatibility Leukocyte Antigen-binding Supermotifs Predict Broadly Cross-reactive Cytotoxic T Lymphocyte Responses in Patients with Acute Hepatitis," <i>J. Clin. Invest.</i> 100:503-513, The American Society for Clinical Investigation, Inc. (1997)	
	NPL5	Bertoni, R., <i>et al.</i> , "Human Class I Supertypes and CTL Repertoires Extend to Chimpanzees," <i>J. Immunol.</i> 161:4447-4455, American Association of Immunologists (1998)	
	NPL6	Bjorkman, P.J., <i>et al.</i> , "Structure of the human class I histocompatibility antigen, HLA-A2," <i>Nature</i> 329:506-512, Macmillan Publishers, Ltd. (1987)	
	NPL7	Bjorkman, P.J., <i>et al.</i> , "The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens," <i>Nature</i> 329:512-518, Macmillan Publishers, Ltd. (1987)	
	NPL8	Buus, S., <i>et al.</i> , "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia," <i>Science</i> 242:1045-1047, American Association for the Advancement of Science (1988)	
	NPL9	Carreno, B.M., <i>et al.</i> , "HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides," <i>Proc. Natl. Acad. Sci. USA</i> 87:3420-3424, National Academy Press (1990)	
	NPL10	Corr, M., <i>et al.</i> , "Endogenous Peptides of a Soluble Major Histocompatibility Complex Class I Molecule, H-2L <sup>d</sup> <sub>s</sub> : Sequence Motif, Quantitative Binding, and Molecular Modeling of the Complex," <i>J. Exp. Med.</i> 176:1681-1692, Rockefeller University Press (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	2	of	8	Attorney Docket Number	2473.0260001/EKS/PAC

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T <sup>2</sup>
	NPL11	De Bruijn, M.L.H., <i>et al.</i> , "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," <i>Eur. J. Immunol.</i> 21:2963-2970, VCH Verlagsgesellschaft mbH (1991)	
	NPL12	Del Val, M., <i>et al.</i> , "Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein," <i>Cell</i> 66:1145-1153, Cell Press (1991)	
	NPL13	Deres, K., <i>et al.</i> , "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> 342:561-564, Macmillan Publishers, Ltd. (1989)	
	NPL14	DiBrino, M., <i>et al.</i> , "HLA-A1 and HLA-A3 T Cell Epitopes Derived from Influenza Virus Proteins Predicted from Peptide Binding Motifs," <i>J. Immunol.</i> 151:5930-5935, The Association of Immunologists (1993)	
	NPL15	DiBrino, M., <i>et al.</i> , "Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides," <i>Proc. Natl. Acad. Sci. USA</i> 90:1508-1512, National Academy Press (1993)	
	NPL16	Ding, Y.-H., <i>et al.</i> , "Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Acids," <i>Immunity</i> 8:403-11, Cell Press (1998)	
	NPL17	Eisenlohr, L.C., <i>et al.</i> , "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> 175:481-487, The Rockefeller University Press (1992)	
	NPL18	Engelhard, V.H., "Structure of peptides associated with MHC Class I molecules," <i>Curr. Opin. Immunol.</i> 6:13-23, Current Biology, Ltd. (1994)	
	NPL19	Falk, K., <i>et al.</i> , "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," <i>Nature</i> 351:290-296, Macmillan Publishers, Ltd. (1991)	
	NPL20	Falk, K., <i>et al.</i> , "MHC peptide motif register. Peptide motifs of HLA-B35 and -B37 molecules," <i>Immunogenetics</i> 38:161-162, Springer-Verlag (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet		3	of	8	Attorney Docket Number
					2473.0260001/EKS/PAC

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher		
	NPL21	Falk, K., <i>et al.</i> , "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Natl. Acad. Sci. USA</i> 90:12005-12009, National Academy Press (1993)		T <sup>2</sup>
	NPL22	Falk, K., <i>et al.</i> , "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules," <i>Immunogenetics</i> 39:230-242, Springer-Verlag (1994)		
	NPL23	Falk, K., <i>et al.</i> , "Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules," <i>Immunogenetics</i> 40:238-241, Springer-Verlag (1994)		
	NPL24	Foon, K.A., "Biological Response Modifiers: The New Immunotherapy," <i>Cancer Res.</i> 49:1621-1639, American Association for Cancer Research (1989)		
	NPL25	Geysen, H.M., <i>et al.</i> , "Cognitive Features of Continuous Antigenic Determinants," <i>J. Mol. Recognit.</i> 1:32-41, Heyden & Sons, Ltd. (1988)		
	NPL26	Guo, H.-C., <i>et al.</i> , "Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle," <i>Nature</i> 360:364-366, Macmillan Publishers, Ltd. (1992)		
	NPL27	Henderson, R.A., <i>et al.</i> , "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation," <i>Science</i> 255:1264-1266, American Association for the Advancement of Science (1992)		
	NPL28	Hill, A., <i>et al.</i> , "Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7," <i>Eur. J. Immunol.</i> 25:18-24, VCH Verlagsgesellschaft mbH (1995)		
	NPL29	Hunt, D.F., <i>et al.</i> , "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 255:1261-1263, American Association for the Advancement of Science (1992)		
	NPL30	Ishioka, G.Y., <i>et al.</i> , "Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes," <i>J. Immunol.</i> 162:3915-3925, The American Association of Immunologists (1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet		4	of	8	Attorney Docket Number
2473.0260001/EKS/PAC					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T <sup>2</sup>
	NPL31	Jameson, S.C., and Bevan, M.J., "Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a K <sup>b</sup> -restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs," <i>Eur. J. Immunol.</i> 22:2663-2667, VCH Verlagsgesellschaft mbH (1992)	
	NPL32	Jardetzky, T.S., et al., "Identification of self peptides bound to purified HLA-B27," <i>Nature</i> 353:326-329, Macmillan Publishers, Ltd. (1991)	
	NPL33	Kannagi, M., et al., "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cells," <i>J. Virol.</i> 66:2928-2933, American Society for Microbiology (1992)	
	NPL34	Kast, W.M., et al., "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287, National Academy Press (1991)	
	NPL35	Kast, W.M., et al., "Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination," <i>Eur. J. Immunol.</i> 23:1189-1192, VCH Verlagsgesellschaft mbH (1993)	
	NPL36	Krieger, J.I., et al., "Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition," <i>J. Immunol.</i> 146:2331-2340, American Association of Immunologists (1991)	
	NPL37	Lipford, G.B., et al., "Primary in Vivo Responses to Ovalbumin. Probing the Predictive Value of the K <sup>b</sup> Binding Motif," <i>J. Immunol.</i> 150:1212-1222, The American Association of Immunologists (1993)	
	NPL38	Maryanski, J.L., et al., "Synthetic peptides as antigens and competitors in recognition by H-2-restricted cytolytic T cells specific for HLA," <i>J. Exp. Med.</i> 167:1391-1405, Rockefeller University Press (1988)	
	NPL39	Maryanski, J.L., et al., "Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers," <i>Cell</i> 60:63-72, Cell Press (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet		5	of	8	Attorney Docket Number
					2473.0260001/EKS/PAC

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T <sup>2</sup>
	NPL40	Morrison, J., <i>et al.</i> , "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 22:903-907, VCH Verlagsgesellschaft mbH (1992)	
	NPL41	Niedermann, G., <i>et al.</i> , "The proteolytic fragments generated by vertebrate proteasomes: Structural relationships to major histocompatibility complex class I binding peptides," <i>Proc. Natl. Acad. Sci. USA</i> 93:8572-8577, National Academy Press (1996)	
	NPL42	Ochoa-Garay, J., <i>et al.</i> , "The ability of peptides to induce cytotoxic T cells <i>in vitro</i> does not strongly correlate with their affinity for the H-2L <sup>d</sup> molecule: implications for vaccine design and immunotherapy," <i>Mol. Immunol.</i> 34:273-281, Elsevier Science, Ltd. (1997)	
	NPL43	Pamer, E.G., <i>et al.</i> , "Precise prediction of a dominant class I MHC-restricted epitome of <i>Listeria monocytogenes</i> ," <i>Nature</i> 353:852-855, Macmillan Publishers, Ltd. (1991)	
	NPL44	Parham, P., <i>et al.</i> , "The Origins of HLA-A,B,C Polymorphism," <i>Immunol. Rev.</i> 143:141-180, Munksgaard (1995)	
	NPL45	Parker, K.C., <i>et al.</i> , "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 267:5451-5459, American Society for Biochemistry and Molecular Biology, Inc. (1992)	
	NPL46	Parker, K.C., <i>et al.</i> , "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2," <i>J. Immunol.</i> 149:3580-3587, American Association of Immunologists (1992)	
	NPL47	Rammensee, H.-G., <i>et al.</i> , "Peptides Naturally Presented by MHC Class I Molecules," <i>Annu. Rev. Immunol.</i> 11:213-244, Annual Reviews, Inc. (1993)	
	NPL48	Rammensee, H.-G., <i>et al.</i> , "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:178-228, Springer-Verlag (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	<i>To Be Assigned</i>
Sheet		6	of	8	Attorney Docket Number
					2473.0260001/EKS/PAC

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T <sup>2</sup>
	NPL49	Reddehase, M.J., <i>et al.</i> , "A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes," <i>Nature</i> 337:651-653, Macmillan Publishers, Ltd. (1989)	
	NPL50	Romero, P., <i>et al.</i> , "H-2K <sup>d</sup> -restricted Antigenic Peptides Share a Simple Binding Motif," <i>J. Exp. Med.</i> 174:603-612, Rockefeller University Press (1991)	
	NPL51	Rothbard, J.B., "Major histocompatibility complex-peptide interactions," <i>Curr. Opin. Immunol.</i> 2:99-105, Current Biology, Ltd. (1989)	
	NPL52	Rötzschke, O., <i>et al.</i> , "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348:252-254, Macmillan Publishers, Ltd. (1990)	
	NPL53	Rötzschke, O., <i>et al.</i> , "Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y," <i>Science</i> 249:283-287, American Association for the Advancement of Science (1990)	
	NPL54	Rötzschke, O., and Falk, K., "Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway," <i>Immunol. Today</i> 12:447-455, Elsevier Science Publishers, Ltd. (1991)	
	NPL55	Rötzschke, O., <i>et al.</i> , "Peptide motifs of closely related HLA class I molecules encompass substantial differences," <i>Eur. J. Immunol.</i> 22:2453-2456, VCH Verlagsgesellschaft mbH (1992)	
	NPL56	Rötzschke, O., and Falk, K., "Origin, structure and motifs of naturally processed MHC class II ligands," <i>Curr. Opin. Immunol.</i> 6:45-51, Current Biology, Ltd. (1994)	
	NPL57	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in <i>Peptide Hormones</i> , Parsons, J.A., ed., University Park Press, Baltimore, MD, pp.1-7 (1976)	
	NPL58	Ruppert, J., <i>et al.</i> , "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-937, Cell Press (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet		7	of	8	Attorney Docket Number
					2473.0260001/EKS/PAC

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T <sup>2</sup>
	NPL59	Schulz, M., et al., "Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide," <i>Eur. J. Immunol.</i> 21:1181-1185, VCH Verlagsgesellschaft mbH (1991)	
	NPL60	Sette, A., et al., "Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis," <i>Proc. Natl. Acad. Sci. USA</i> 86:3296-3300, National Academy Press (1989)	
	NPL61	Sette, A., et al., "Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules," <i>J. Immunol.</i> 147:3893-3900, The American Association of Immunologists (1991)	
	NPL62	Sette, A., et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-5592, The American Association of Immunologists (1994)	
	NPL63	Shastri, N., et al., "Presentation of Endogenous Peptide/MHC Class I Complexes Is Profoundly Influenced by Specific C-Terminal Flanking Residues," <i>J. Immunol.</i> 155: 4339-4346, The American Association of Immunologists (1995)	
	NPL64	Sherman, L.A., et al., "Extracellular Processing of Peptide Antigens That Bind Class I Major Histocompatibility Molecules," <i>J. Exp. Med.</i> 175:1221-1226, The Rockefeller University Press (1992)	
	NPL65	Shimojo, N., et al., "Specificity of peptide binding by the HLA-A2.1 molecule," <i>J. Immunol.</i> 143:2939-2947, The American Association of Immunologists (1989)	
	NPL66	Sidney, J., et al., "Several HLA Alleles Share Overlapping Peptide Specificities," <i>J. Immunol.</i> 154:247-259, The American Association of Immunologists (1995)	
	NPL67	Threlkeld, S.C., et al., "Degenerate and Promiscuous Recognition by CTL of Peptides Presented by the MHC Class I A3-like Superfamily. Implications for Vaccine Development," <i>J. Immunol.</i> 159:1648-1657, The American Association of Immunologists (1997)	
	NPL68	Wentworth, P.A., et al., "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," <i>Eur. J. Immunol.</i> 26:97-101, VCH Verlagsgesellschaft mbH (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	BAKER, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet		8	of	8	Attorney Docket Number
					2473.0260001/EKS/PAC

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher		T <sup>2</sup>
	NPL69	Whitton, J.L., <i>et al.</i> , "Molecular Analyses of a Five-Amino-Acid Cytotoxic T-Lymphocyte (CTL) Epitope: an Immunodominant Region Which Induces Nonreciprocal CTL Cross-Reactivity," <i>J. Virol.</i> 63:4303-4310, American Society for Microbiology (1989)		
	NPL70	Yewdell, J.W., and Bennink, J.R., "Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes," <i>Adv. Immunol.</i> 52:1-123, Academic Press (1992)		
	NPL71	York, I.A., and Rock, K.L., "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-396, Annual Reviews, Inc. (1996)		
	NPL72	Zhang, Q-J., <i>et al.</i> , "An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins," <i>Proc. Natl. Acad. Sci. USA</i> 90:2217-2221, National Academy Press (1993)		
	NPL73	Parker, K.C., <i>et al.</i> , "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>J. Immunol.</i> 152:163-175, The American Association of Immunologists (1994)		
	NPL74	Dialog File 351, Accession No. 7180926, Derwent WPI English language abstract for EP 0 226 513 (Document AM1)		
	NPL75	Dialog File 351, Accession No. 9263567, Derwent WPI English language abstract for WO 92/21033 (Document AP1)		
	NPL76	Dialog File 351, Accession No. 9888606, Derwent WPI English language abstract for WO 94/11738 (Document AN2)		
	NPL77	U.S. Patent Application No. 09/189,702, Sette <i>et al.</i> , filed November 10, 1998 (NOT PUBLISHED)		

526377\_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BAKER *et al.*

Appl. No.: 10/551,209

§ 371 Date: September 28, 2005

For: **Methods of Identifying Optimal Variants of Peptide Epitopes**

Confirmation No.: 8322

Art Unit: 1644

Examiner: *To be assigned*

Atty. Docket: 2473.0260001/EKS/PAC

**First Supplemental Information Disclosure Statement**

**Under 37 C.F.R. § 1.97(b)**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed herewith in connection with the above-captioned application.

Copies of documents **FP22** to **FP31** and **NPL80** to **NPL157** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US16** to **US35**, cited on the attached IDS Form, PTO/SB/08A, are not submitted. In addition, a copy of document **NPL158** is not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent

application (or portion of the application which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following co-pending U.S. Patent Application, which is directed to related technical subject matter:

Application No. 10/817,970, inventors Grey *et al.*, filed April 6, 2004; pending and listed on accompanying PTO/SB/08B as Document **NPL158**;

The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

 Reg # 54,325  
*for* Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913


Date: \_\_\_\_\_

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
526872v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

JUL 11 2006


**FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

*Complete If Known*

				Application Number	10/551,209
				§ 371 Date	September 28, 2005
				First Named Inventor	Baker, Denise Marie
				Art Unit	1644
				Examiner Name	To Be Assigned
				Attorney Docket Number	2473.0260001/EKS/PAC
Sheet	1	of	2		

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If Known)				
	US16	4,235,877		11/25/1980	Fullerton	
	US17	4,487,715		12/11/1984	Nitecki <i>et al.</i>	
	US18	4,599,230		07/08/1986	Milich <i>et al.</i>	
	US19	4,837,028		06/06/1989	Allen	
	US20	5,013,548		05/07/1991	Haynes <i>et al.</i>	
	US21	5,128,319		07/07/1992	Arlinghaus	
	US22	5,736,142		04/07/1998	Sette <i>et al.</i>	
	US23	5,783,567		07/21/1998	Hedley <i>et al.</i>	
	US24	6,037,135		03/14/2000	Kubo <i>et al.</i>	
	US25	6,413,935		07/02/2002	Sette <i>et al.</i>	
	US26	6,419,931		07/16/2002	Vitiello <i>et al.</i>	
	US27	6,602,510		08/05/2003	Fikes <i>et al.</i>	
	US28	2002/0160960		10/31/2002	Sette <i>et al.</i>	
	US29	2002/0168374		11/14/2002	Kubo <i>et al.</i>	
	US30	2003/0143672		07/31/2003	Tangri <i>et al.</i>	
	US31	2003/0216342		11/20/2003	Fikes <i>et al.</i>	
	US32	2003/0216343		11/20/2003	Fikes <i>et al.</i>	
	US33	2004/0096445		05/20/2004	Sidney <i>et al.</i>	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>4</sup> Kind Code <sup>5</sup> (in known)				
	FP22	EP 0 378 881	06/09/1993	Eniricerche S.p.A.		
	FP23	EP 0 429 816	06/05/1991	F. Hoffmann-La Roche AG		
	FP24	EP 0 433 242	06/19/1991	Fondazione Andrea Cesalpino		
	FP25	WO 93/03764	03/04/1993	Cytel Corporation		
	FP26	WO 94/20127	09/15/1994	Cytel Corporation		
	FP27	WO 95/07707	03/23/1995	Cytel Corporation		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Transaction is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**Substitute for form 1449A/PTO**

**FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete If Known	
Application Number	10/551,209
§ 371 Date	September 28, 2005
First Named Inventor	Baker, Denise Marie
Art Unit	1644
Examiner Name	To Be Assigned
Attorney Docket Number	2473.0260001/EKS/PAC


## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>4</sup> Kind Code <sup>5</sup> (in known)				
	FP28	WO 96/22067	07/25/1996	United Biomedical		
	FP29	WO 97/41440	11/06/1997	Rijksuniversiteit te Leiden and Seed Capital Investments		
	FP30	WO 97/34617	09/25/1997	Cytel Corporation		
	FP31	WO 01/00225	01/04/2001	Epimmune Inc.		
Examiner Signature				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

here it English language translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number	10/551,209				
§ 371 Date	September 28, 2005				
First Named Inventor	Baker, Denise Marie				
Art Unit	1644				
Examiner Name	To Be Assigned				
Sheet	1	of	8	Attorney Docket Number	2473,0260001/EKS/PAC

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL80	Alexander, J., et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <i>Immunity</i> 1:751-761, Cell Press (1994)	
	NPL81	Arndt, S.O., et al., "Selection of the MHC Class II-Associated Peptide Repertoire by HLA-DM," <i>Immunol. Res.</i> 16:261-272, Humana Press (1997)	
	NPL82	Barouch, D., et al., "HLA-A2 Subtypes Are Functionally Distinct in Peptide Binding and Presentation," <i>J. Exp. Med.</i> 182:1847-1856, Rockefeller University Press (1995)	
	NPL83	Bender, A., et al., "Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood," <i>J. Immunol. Methods</i> 196:121-135, Elsevier Science (1996)	
	NPL84	Ben-Yedid, T., and Arnon, R., "Design of peptide and polypeptide vaccines," <i>Curr. Opin. Biotechnol.</i> 8:442-448, Current Biology, Ltd. (1997)	
	NPL85	Carbone, F.R., and Bevan, M.J., "Induction of Ovalbumin-Specific Cytotoxic T Cells by In Vivo Peptide Immunization," <i>J. Exp. Med.</i> 169:603-612, Rockefeller University Press (1989)	
	NPL86	Carbone, F.R., et al., "Induction of Cytotoxic T Lymphocytes by Primary In Vitro Stimulation with Peptides," <i>J. Exp. Med.</i> 167:1767-1779, Rockefeller University Press (1988)	
	NPL87	Cassell, D., and Forman, J., "Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes," <i>Ann. N.Y. Acad. Sci.</i> 532:51-60, New York Academy Of Sciences (1991)	
	NPL88	Deres, K., et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> 342:561-564, Nature Publishing Group (1989)	
	NPL89	del Guercio, M-F., et al., "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses in vivo," <i>Vaccine</i> 15:441-448, Elsevier Science (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	8	Attorney Docket Number	2473,0260001/EKS/PAC
-------	---	----	---	------------------------	----------------------

**Complete If Known**

Application Number	10/551,209
§ 371 Date	September 28, 2005
First Named Inventor	Baker, Denise Marie
Art Unit	1644
Examiner Name	To Be Assigned

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL90	DiBrino, M., et al., "Endogenous Peptides with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8," J. Immunol. 152:620-631, American Association of Immunologists (1994)	
	NPL91	DiBrino, M., et al., "The HLA-B14 Peptide Binding Site Can Accommodate Peptides with Different Combinations of Anchor Residues," J. Biol. Chem. 269:32426-32434, American Society for Biochemistry and Molecular Biology (1994)	
	NPL92	Donnelly, J.J., et al., "DNA Vaccines," Annu. Rev. Immunol. 15:617-648, Annual Reviews Inc. (1997)	
	NPL93	Francis, M.J., et al., "Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants," Nature 330:168-170, Nature Publication Group (1987)	
	NPL94	Fynan, E.F., et al., "DNA vaccines: Protective immunizations by parental, mucosal, and gene-gun inoculations," Proc. Natl. Acad. Sci. USA 90:11478-11482, National Academy of Sciences (1993)	
	NPL95	Gileadi, U., et al., "Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes," Eur. J. Immunol. 29:2213-2222, WILEY-VCH Verlag GmbH (1999)	
	NPL96	Golzano, J., et al., "Polarity of immunogens: implications for vaccine design," Eur. J. Immunol. 20:2363-2366, VCH Verlagsgesellschaft mbH (1990)	
	NPL97	Gulukota, K., et al., "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules," J. Mol. Biol. 267:1258-1267, Academic Press Limited (1997)	
	NPL98	Hahn, Y.S., et al., "CD8+ T Cell Recognition of an Endogenously Processed Epitope is Regulated Primarily by Residues within the Epitope," J. Exp. Med. 176:1335-1341, Rockefeller University Press (1992)	
	NPL99	Hahn, Y.S., et al., "Presentation of Viral Antigen to Class I Major Histocompatibility Complex-Restricted Cytotoxic T Lymphocyte. Recognition of an Immunodominant Influenza Hemagglutinin Site by Cytotoxic T Lymphocyte is Independent of the Position of the Site in the Hemagglutinin Translation Product," J. Exp. Med. 174:733-736, Rockefeller University Press (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	8	Attorney Docket Number	2473,0260001/EKS/PAC
-------	---	----	---	------------------------	----------------------

**Complete If Known**

Application Number	10/551,209
§ 371 Date	September 28, 2005
First Named Inventor	Baker, Denise Marie
Art Unit	1644
Examiner Name	To Be Assigned

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL100	Hammer, J., et al., "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning," <i>J. Exp. Med.</i> 180:2353-2358, Rockefeller University Press (1994)	
	NPL101	Hill, C.M., et al., "Exploration of Requirements for Peptide Binding to HLA DRB1*0101 and DRB1*0401," <i>J. Immunol.</i> 152:2890-2898, American Association of Immunologists (1994)	
	NPL102	Huczko, E.L., et al., "Characteristics of Endogenous Peptides Eluted from the Class I MHC Molecule HLA-B7 Determined by Mass Spectrometry and Computer Modeling," <i>J. Immunol.</i> 151:2572-2587, American Association of Immunologists (1993)	
	NPL103	Ishioka, G.Y., et al., "Class I MHC-restricted, peptide specific cytotoxic T lymphocytes generated by peptide priming in vivo," in <i>Vaccines90: Modern Approaches to New Vaccines Including Prevention of AIDS</i> , Brown, F., et al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 7-11 (1990)	
	NPL104	Ishioka, G.Y., et al., "Induction of Class I MHC-Restricted, Peptide-Specific Cytolytic T Lymphocytes by Peptide Priming In Vivo," <i>J. Immunol.</i> 143:1094-1100, American Association of Immunologists (1989)	
	NPL105	Jardetzky, T.S., et al., "Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding," <i>EMBO J.</i> 9:1797-1803, Oxford University Press (1990)	
	NPL106	Kast, W.M., et al., "Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287, National Academy of Sciences (1991)	
	NPL107	Kondo, A., et al., "Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes," <i>Immunogenetics</i> 45:249-258, Springer-Verlag (1997)	
	NPL108	Kubitscheck, U., et al., "Peptide Binding to Class I Molecules of the Major Histocompatibility Complex on the Surface of Living Target Cells," <i>Scand. J. Immunol.</i> 36:341-348, Blackwell Scientific Publications (1992)	
	NPL109	Kubo, R.T., et al., "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles," <i>J. Immunol.</i> 152:3913-3924, American Association of Immunologists (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	8	Attorney Docket Number	2473,0260001/EKS/PAC
-------	---	----	---	------------------------	----------------------

**Complete If Known**

<i>Application Number</i>	10/551,209
<i>§ 371 Date</i>	September 28, 2005
<i>First Named Inventor</i>	Baker, Denise Marie
<i>Art Unit</i>	1644
<i>Examiner Name</i>	To Be Assigned

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL110	Kumar, A., et al., "Universal T Helper Cell Determinants Enhance Immunogenicity of a Plasmodium falciparum Merozoite Surface Antigen Peptide," J. Immunol. 148:1499-1505, American Association of Immunologists (1992)	
	NPL111	Lasarte, J.-J., et al., "Induction of Cytotoxic T Lymphocytes in Mice against the Principal Neutralizing Domain of HIV-1 by Immunization with an Engineered T-Cytotoxic-T-Helper Synthetic Helper Peptide Construct," Cell. Immunol. 141:211-218, Academic Press Inc. (1992)	
	NPL112	Madden, D.R., et al., "The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation," Nature 353:321-325, Nature Publishing Group (1991)	
	NPL113	Maier, R., et al., "Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing," Immunogenetics 40:306-308, Springer-Verlag (1994)	
	NPL114	Martinon, F., et al., "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant," J. Immunol. 149:3416-3422, American Association of Immunologists (1992)	
	NPL115	Niedermann, G., et al., "Contribution of Proteasome-Mediated Proteolysis to the Hierarchy of Epitopes Presented by Major Histocompatibility Complex Class I Molecules," Immunity 2:289-299, Cell Press (1995)	
	NPL116	Niedermann, G., et al., "The specificity of proteasomes: impact on MHC class I processing and presentation of antigens," Immunol. Rev. 172:29-48, Munksgaard (December 1999)	
	NPL117	Nikolić-Žugić, J., and Carbone, F.R., "Peptide Presentation by Class-I Major Histocompatibility Complex Molecules," Immunol. Res. 10:54-65, S. Karger AG (1991)	
	NPL118	O'Sullivan, D., et al., "Characterization of the Specificity of Peptide Binding to Four DR Haplotypes," J. Immunol. 145:1799-1808, American Association of Immunologists (1990)	
	NPL119	O'Sullivan, D., et al., "On the Interaction of Promiscuous Antigenic Peptides with Different DR Alleles," J. Immunol. 147:2663-2669, American Association of Immunologists (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	5	of	8	Attorney Docket Number	2473,0260001/EKS/PAC
-------	---	----	---	------------------------	----------------------

**Complete If Known**

Application Number	10/551,209
§ 371 Date	September 28, 2005
First Named Inventor	Baker, Denise Marie
Art Unit	1644
Examiner Name	To Be Assigned

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL120	Panina-Bordignon, P., et al., "Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells," Eur. J. Immunol. 19:2237-2242, VCH Verlagsgesellschaft mbH (1989)	
	NPL121	Paz, P., et al., "Discrete Proteolytic Intermediates in the MHC Class I Antigen Processing Pathway and MHC I-Dependent Peptide Trimming in the ER," Immunity 11:241-251, Cell Press (1999)	
	NPL122	Penna, A., et al., "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen," J. Exp. Med. 174:1565-1570, Rockefeller University Press (1991)	
	NPL123	Pryjma, J., et al., "Induction and Suppression of Immunoglobulin Synthesis in Cultures of Human Lymphocytes: Effects of Pokeweed Mitogen and Staphylococcus Aureus Cowan I," J. Immunol. 124:656-661, Williams & Wilkins Co. (1980)	
	NPL124	Rahemtulla, A., et al., "Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4," Nature 353:180-183, Nature Publishing Group (1991)	
	NPL125	Rammensee, H-G., et al., "SYFPEITHI: database for MHC ligands and peptide motifs," Immunogenetics 50:213-219, Springer-Verlag (1999)	
	NPL126	Reitermann, A., et al., "Lipopeptide Derivatives of Bacterial Lipoprotein Constitute Potent Immune Adjuvants Combined with or Covalently Coupled to Antigen or Hapten," Biol. Chem. Hoppe Seyler 370:343-352, Walter De Gruyter (1989)	
	NPL127	Restifo, N.P., et al., "Antigen Processing In Vivo and the Elicitation of Primary CTL Responses," J. Immunol. 154:4414-4422, American Association of Immunologists (1995)	
	NPL128	Saper, M.A., et al., "Refined Structure of the Human Histocompatibility Antigen HLA-A2 at 2.6 Å Resolution," J. Mol. Biol. 219:277-319, Academic Press Ltd. (1991)	
	NPL129	Schaeffer, E.B., et al., "Relative contribution of 'determinant selection' and 'holes in the T-cell repertoire' to T-cell responses," Proc. Natl. Acad. Sci. USA 86:4649-4653, National Academy of Sciences (1989)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 8 Attorney Docket Number 2473,0260001/EKS/PAC

**Complete If Known**

<i>Application Number</i>	10/551,209
<i>§ 371 Date</i>	September 28, 2005
<i>First Named Inventor</i>	Baker, Denise Marie
<i>Art Unit</i>	1644
<i>Examiner Name</i>	To Be Assigned

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL130	Schumacher, T.N.M., et al., "Peptide selection by MHC class I molecules," Nature 350:703-706, Nature Publishing Group (1991)	
	NPL131	Sette, A., and Sidney, J., "HLA supertypes and supermotifs: a functional perspective on HLA polymorphism," Curr. Opin. Immunol. 10:478-482, Current Biology Publications (1998)	
	NPL132	Sette, A., et al., "A Novel Approach to the Generation of High Affinity Class II-Binding Peptides," J. Immunol. 145:1809-1813, American Association of Immunologists (1990)	
	NPL133	Sette, A., et al., "Effect of Conformational Propensity of Peptide Antigens in Their Interaction with MHC Class II Molecules," J. Immunol. 143:1268-1273, American Association of Immunologists (1989)	
	NPL134	Sette, A., et al., "Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays," Mol. Immunol. 31:813-822, Pergamon Press (1994)	
	NPL135	Sidney, J., et al., "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules," Hum. Immunol. 45:79-93, Elsevier Science Inc. (1996)	
	NPL136	Sidney, J., et al., "Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs," Immunol. Today 17:261-266, Elsevier Science (1996)	
	NPL137	Sidney, J., et al., "The HLA-A*0207 Peptide Binding Repertoire is Limited to a Subset of the A*0201 Repertoire," Hum. Immunol. 58:12-20, Elsevier Science Inc. (November 1997)	
	NPL138	Sinigaglia, F., and Hammer, J., "Defining rules for the peptide-MHC class II interaction," Curr. Opin. Immunol. 6:52-56, Current Biology Ltd. (1994)	
	NPL139	Southwood, S., et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires," J. Immunol. 160:3363-3373; American Association of Immunologists (1998)	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete If Known</i>	
				<i>Application Number</i>	10/551,209
				<i>§ 371 Date</i>	September 28, 2005
				<i>First Named Inventor</i>	Baker, Denise Marie
				<i>Art Unit</i>	1644
				<i>Examiner Name</i>	To Be Assigned
Sheet	7	of	8	<i>Attorney Docket Number</i>	2473,0260001/EKS/PAC

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL140	Sprent, J., and Schaefer, M., "Properties of Purified T Cell Subsets. I. In Vitro Responses to Class I vs. Class II H-2 Alloantigens," <i>J. Exp. Med.</i> 162:2068-2088, Rockefeller University Press (1985)	
	NPL141	Stark, J.M., et al., "Immunogenicity of lipid-conjugated antigens. I. The Influence of Chain Length and Degree of Conjugation on Induction of Antibody in Mice," <i>Immunology</i> 39:345-352, Blackwell Scientific Publications (1980)	
	NPL142	Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exp. Hematol.</i> 24:859-862, Elsevier Science Inc. (1996)	
	NPL143	Sudo, T., et al., "Differences in MHC Class I Self Peptide Repertoires Among HLA-A2 Subtypes," <i>J. Immunol.</i> 155:4749-4756, American Association of Immunologists (1995)	
	NPL144	Sugawara, S., et al., "A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3," <i>J. Immunol. Methods</i> 100:83-90, Elsevier Science (1987)	
	NPL145	Tam, J.P., and Lu, Y.-A., "Vaccine engineering: Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 86:9084-9088, National Academy of Sciences (1989)	
	NPL146	Townsend, A., and Bodmer, H., "Antigen Recognition by Class I-Restricted T Lymphocytes," <i>Ann. Rev. Immunol.</i> 7:601-624, Annual Reviews, Inc. (1989)	
	NPL147	von Boehmer, H., and Haas, W., "Distinct Ir Genes for Helper and Killer Cells in the Cytotoxic Response to H-Y Antigen," <i>J. Exp. Med.</i> 150:1134-1142, Rockefeller University Press (1979)	
	NPL148	Watari, E., et al., "A Synthetic Peptide Induces Long-Term Protection from Lethal Infection with Herpes Simplex Virus 2," <i>J. Exp. Med.</i> 165:459-470, Rockefeller University Press (1987)	
	NPL149	Wentworth, P.A., et al., "In Vitro Induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," <i>Mol. Immunol.</i> 32:603-612, Elsevier Science Ltd. (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	8	of	8	Attorney Docket Number	2473,0260001/EKS/PAC
-------	---	----	---	------------------------	----------------------

**Complete If Known**

Application Number	10/551,209
§ 371 Date	September 28, 2005
First Named Inventor	Baker, Denise Marie
Art Unit	1644
Examiner Name	To Be Assigned

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL150	Wherry, E.J., et al., "The Induction of Virus-Specific CTL as a Function of Increasing Epitope Expression: Responses Rise Steadily Until Excessively High Levels of Epitope Are Attained," J. Immunol. 163:3735-3745, American Association of Immunologists (1999)	
	NPL151	Widmann, C., et al., "T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides," J. Immunol. Meth. 155:95-99, Elsevier Science Publishers B.V. (1992)	
	NPL152	Wiesmüller, K-H., et al., "Lipopeptide-Helper-T-Cell Epitope-CTL Epitope Conjugate Induces Antibodies Against the CTL Epitope," Innovation Perspective Solid Phase Synthesis Collect. Papers, Int. Symp. 2nd, pp. 499-502 (1991)	
	NPL153	Wiesmüller, K-H., et al., "Novel low-molecular-weight synthetic vaccine against foot-and mouth disease containing a potent B cell and macrophage activator," Vaccine 7:29-33, Butterworth & Co. (1989)	
	NPL154	Yewdell, J.W., and Bennink, J.R., "Immunodominance in Major Histocompatibility Complex Class I-Restricted T Lymphocyte Responses," Annu. Rev. Immunol. 17:51-88, Annual Reviews Inc. (1999)	
	NPL155	Zhou, X., et al., "In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides," J. Immunol. Methods 153:193-200, Elsevier Science Publishers B.V. (1992)	
	NPL156	Zinkernagel, R.M., et al., "The Lymphoreticular System in Triggering Virus Plus Self-Specific Cytotoxic T Cells: Evidence for T Help," J. Exp. Med. 147:897-911, Rockefeller University Press (1978)	
	NPL157	Altuvia, Y. et al., "A Structure-Based Algorithm to Predict Potential Binding Peptides to MHC Molecules with Hydrophobic Binding Pockets," Human Immunol. 58:1-11, Elsevier Science Inc. (1997)	
	NPL158	U.S. Patent Application No. 10/817,970, Grey et al., filed April 6, 2004 (NOT PUBLISHED)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.